Interferon-gamma treatment in azole-resistant oropharyngeal candidiasis
17 December 2000. Related: Conference reports, Coinfections and complications.
Conference reports
Further reports of avascular necrosis (AVN) and changes in bone mineral density (BMD)
17 December 2000. Related: Conference reports, Side effects.
Clinical issues arising from a single treatment interruption
17 December 2000. Related: Conference reports, Antiretrovirals.
A review of new anti-HIV drugs in development
17 December 2000. Related: Conference reports, Antiretrovirals.
Antiretroviral therapy in children, women and intravenous drug users
17 December 2000. Related: Conference reports, Women's health, Paediatric care.
Treatment of HIV+ subjects co-infected with hepatitis B or C: safety and efficacy comparison of ABT 378/r versus nelfinavir from a phase III blinded randomised clinical trial
17 December 2000. Related: Conference reports, Hepatitis coinfection.
Interferon-alpha and ribavarin therapy for hepatitis C in HIV coinfected patients
17 December 2000. Related: Conference reports, Hepatitis coinfection.
Lack of significant viral load alterations of hepatitis B virus (HBV) and hepatitis C virus (HCV) during treatment with interleukin-2 and HAART
17 December 2000. Related: Conference reports, Hepatitis coinfection.
Child protection issues around starting efavirenz in a mother on maintenance methadone
17 December 2000. Related: Conference reports.
Structured treatment interruptions
17 December 2000. Related: Conference reports, Treatment strategies.
Adherence and HAART: unique approaches to evaluating and improving adherence discussed
17 December 2000. Related: Conference reports, Antiretrovirals.
Reports on lipodystrophy and metabolic complications
17 December 2000. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Opportunistic infections in the HAART era
17 December 2000. Related: Conference reports, Coinfections and complications.
2nd International Workshop on Adverse Drug Reactions and Lipodystrophy, Toronto, Canada, 13-15 September 2000
17 October 2000. Related: Conference reports.
Lipodystrophy: the current state of play
17 October 2000. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Metabolic effects – bone density and avascular necrosis
17 October 2000. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Lipoatrophy and facial wasting
17 October 2000. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Lactic acidosis
17 October 2000. Related: Conference reports, Side effects.
Lipodystrophy and metabolic changes in children
17 October 2000. Related: Conference reports, Paediatric care.
40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 17-20 September 2000
17 October 2000. Related: Conference reports.
Mitochondrial toxicity reports
17 October 2000. Related: Conference reports, Side effects.
Treatment interruption and salvage therapy
17 October 2000. Related: Conference reports, Drug resistance.
Are gender-related differences in viral load present in infants and children?
17 October 2000. Related: Conference reports, Paediatric care.
Immune reconstitution in children treated with HAART is independent of age
17 October 2000. Related: Conference reports, Paediatric care.
Pharmacokinetics in children and infants
17 October 2000. Related: Conference reports, Paediatric care.
Opportunistic illness and viral hepatitis co-infection
17 October 2000. Related: Conference reports, Coinfections and complications, Hepatitis coinfection.
XIII International AIDS Conference, Durban, South Africa, 9-14th July 2000
16 August 2000. Related: Conference reports.
Mother-to-child transmission, maternal health and women’s access to care
16 August 2000. Related: Conference reports, Pregnancy.
The M in MTCT: questions about HIV-positive mothers
16 August 2000. Related: Conference reports, Pregnancy.
First report of ABT-378/r use in children
16 August 2000. Related: Conference reports, Paediatric care.
Nelfinavir doses should be increased in infants less than 3 months
16 August 2000. Related: Conference reports, Paediatric care.
Metabolic and lipodystropy issues: confusion continues to reign
16 August 2000. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Switching studies: Can viral load be maintained and metabolic or fat redistribution significantly improved?
16 August 2000. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Commentary on STI talk, early entry inhibitor research, increase in viral replication seen in isolates in presence of NNRTIs
16 August 2000. Related: Conference reports.
New developments in affordable antiretroviral therapy: intermittent treatment
16 August 2000. Related: Conference reports, Treatment strategies.
Cannabinoids effect on HIV-1 viral load and appetite
16 August 2000. Related: Conference reports.
IL-2 without HAART may delay need for antiretroviral treatment
16 August 2000. Related: Conference reports.
New potential dual NNRTI-based combinations
16 August 2000. Related: Conference reports, Antiretrovirals.
Once-daily protease-based regimens
16 August 2000. Related: Conference reports, Antiretrovirals, Treatment strategies.
Mitochondrial DNA (mtDNA) damage in semen as surrogate marker for nucleoside analogue toxicity
16 August 2000. Related: Conference reports, Side effects.
Antiretrovirals and fertility – implications for couples looking to conceive
16 August 2000. Related: Conference reports.
Incidence of adverse events at 4 weeks correlates with adherence and virologic failure at 4 months
16 August 2000. Related: Conference reports, Side effects.
Prednisone and nevirapine rash
16 August 2000. Related: Conference reports, Side effects.
The prevalence of hypogonadism in HIV positive patients receiving HAART
16 August 2000. Related: Conference reports, Other news.
Human papilloma virus and HIV
16 August 2000. Related: Conference reports, Coinfections and complications.
4th International Workshop on HIV Drug Resistance and Treatment Strategies, 12-16 June 2000, Sitges, Spain
16 July 2000. Related: Conference reports.
Tenofovir (PMPA), defining cross-resistance profiles
16 July 2000. Related: Conference reports, Drug resistance.
DAPD shows activity in vitro against multidrug-resistant HIV but initial results from monotherapy in treatment experienced subjects are disappointing
16 July 2000. Related: Conference reports, Antiretrovirals.
Mycophenalate mofetil in patients with advanced disease and multidrug resistant HIV
16 July 2000. Related: Conference reports, Drug resistance.
Hydroxyurea is active in vitro against multidrug-resistant HIV
16 July 2000. Related: Conference reports, Drug resistance.
ABT-378/r (Lopinavir): defining a resistance profile and the effects of resistance on virological response in experienced patients
16 July 2000. Related: Conference reports, Drug resistance.
Indinavir/ritonavir at 400/400 mg or 800/100 mg as intensification
16 July 2000. Related: Conference reports, Antiretrovirals.
Ritonavir/saquinavir combination: effect of ritonavir dosage
16 July 2000. Related: Conference reports, Antiretrovirals.
What is the significance of blips in viral load?
16 July 2000. Related: Conference reports, Treatment strategies.
Phenotypic resistance testing improves response to therapy: final analysis of VIRA3001
16 July 2000. Related: Conference reports, Drug resistance.
A prospective study of strategic treatment interruptions in patients with chronic HIV-infection
16 July 2000. Related: Conference reports.
Added value of hydroxyurea or IL-2 to STIs remains uncertain
16 July 2000. Related: Conference reports.
Continued benefits from protease inhibitor based therapy despite virological failure
16 July 2000. Related: Conference reports, Drug resistance.
Do resistance mutations disappear off therapy?
16 July 2000. Related: Conference reports, Drug resistance.
Selection of PI mutations during slow decay of VL and resistance after PI failure
16 July 2000. Related: Conference reports, Drug resistance.
Thymidine analogues mutations (TAMS) and other NA-related resistance mutations
16 July 2000. Related: Conference reports, Drug resistance.
Nevirapine vs efavirenz: the SENC trial
16 July 2000. Related: Conference reports, Antiretrovirals.
A warning on simplification strategies: not suitable for all
16 July 2000. Related: Conference reports.
Third International Workshop on Salvage Therapy for HIV Infection, April 12-14, 2000, Chicago, USA
16 June 2000. Related: Conference reports.
Exercise testing in HIV patients with random increased lactic acid levels: evidence for a reduced anaerobic threshold with a pattern of mitochondrial dysfunction
15 June 2000. Related: Conference reports, Side effects.